HGEN News and Press, Humanigen Inc. From 05/06/21

Oppenheimer has initiated shares of Humanigen (HGEN) with an outperform rating as its experimental COVID-19 therapy is "the most investible approach to the maturing COVID-19 pandemic."The firm's $30 price target implies upside of around ~39% based on today's close.Analyst Kevin DeGeeter says ...

Shares of Humanigen (NASDAQ: HGEN) were vaulting 10.8% higher as of 2:47 p.m. EDT on Wednesday. The gain came after the company announced the publishing of results on the online preprint site medRxiv from a phase 3 study evaluating lenzilumab in treating hospitalized COVID-19 patien...

Humanigen ([[HGEN]] +4.7%) is trading higher after the company announced the publication of Phase 3 results of its lead asset lenzilumab in hospitalized COVID-19 patients.The Phase 3 data published online as a pre-print of medrxiv has yet to undergo the peer-review which typically precedes th...

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, announced that results from the lenzilumab P...

Gainers: Regional Health Properties (RHE) +92%, Brooklyn ImmunoTherapeutics (BTX) +32%, Precipio PRPO +30%, Rezolute (RZLT) +28%, Milestone Scientific (MLSS) +15%.Losers: Vaxart VXRT -18%, Regulus Therapeutics RGLS -18%, Humanigen (HGEN)&...

The Reddit community WallStreetBets, or WSB, demonstrated its power by facilitating a massive short-squeeze on GameStop (GME) earlier this year. While the limelight has yet to shift from the healthcare industry, and many stocks in that sector are witnessing steady price increases, we think sp...

Humanigen (HGEN) appointed Adrian Kilcoyne, MD, MBA, MPH, to the newly-created role of Chief Medical Officer, effective immediately.He has significant experience in multinational pharmaceutical and biotechnology companies and a strong clinical background in both Internal Medicine and Public H...

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced the appointment of A...

Should Investors Be Watching These Top Biotech Stocks Now? It has been over a year since the coronavirus pandemic took the world by surprise. As a result, biotech stocks are in the spotlight more than ever on the stock market right now. This would be the case seeing as news ...

Humanigen ([[HGEN]] -2.8%) announced positive data from the Phase 1b portion of the ZUMA-19 trial which involved six patients in two cohorts.The study was designed to evaluate the efficacy and safety of Lenzilumab with CAR-T in diffuse large B-cell lymphoma (DLBCL). The overall ORR ...